Breakthrough discovery could lead to novel malaria vaccines and therapies

Gala­pa­gos has tem­porar­i­ly stopped en­rolling pa­tients in­to an ear­ly-phase test in pa­tients with mul­ti­ple myelo­ma af­ter a neu­ro­log­i­cal is­sue was raised. Else­where, the biotech ex­pand­ed

Trofinetide is intended to treat Rett syndrome, a neurodevelopmental disorder. Credit: SewCreamStudio/Shutterstock. Acadia Pharmaceuticals has submitted a marketing authorisation application (MAA) to the European Medicines

Last month, BioN­Tech went all-in on VEGF bis­pe­cif­ic an­ti­bod­ies. On Tues­day, to val­i­date its bet, the com­pa­ny shared ear­ly sur­vival da­ta from … Sign up